A Phase 2 interventional study of AVI-4658 (Eteplirsen) and Placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 7 Years to 13 Years. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 8th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 3rd registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 13 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2011.
This study's enrollment of 12 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 2, and was the 2nd registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24 weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD).
For details regarding the roll-over extension study 4658-us-202, please refer to NCT01540409.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Major Inclusion and Exclusion Criteria:
Inclusion Criteria:
A subject must meet all of the following criteria to be eligible for this study.
Exclusion Criteria:
A subject who meets any of the following criteria will be excluded from this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. 50 mg/kg eteplirsen for 28 weeks 2. 30 mg/kg eteplirsen for 28 weeks
Drug: AVI-4658 (Eteplirsen)
3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks. 3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks.
Other: Placebo
Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
Also known as: Eteplirsen- Phosphorodiamidate Morphilino Oligomer
sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
Also known as: Phosphate buffered saline
Change in the Number (%) of Dystrophin Positive Fibers
The primary efficacy endpoint will be based on the pre-treatment and post-treatment change in the number (%) of dystrophin positive fibers as measured in the muscle biopsy tissue on immunohistochemistry (IHC).
Time frame: After 12 weeks for 4 patients who received 50 mg/kg and 2 patients who received placebo. After 24 weeks for 4 patients who received 30 mg/kg and 2 patients who received placebo.
Change From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT)
A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment Change from baseline: 6 Minute Walk Test (6MWT) - Intent to Treat population (ITT)
Time frame: 24 weeks
Change From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT)
A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment of the 6-MWT distance. Change from baseline: 6 Minute Walk Test (6MWT) - modified Intent-to-Treat population (mITT).
Time frame: 24 weeks
| Milestone | AVI-4658 (Eteplirsen) 50 mg/kg | Placebo - Week 12 Biopsy | AVI-4658 (Eteplirsen) 30 mg/kg | Placebo - Week 24 Biopsy |
|---|---|---|---|---|
| Started | 4 | 2 | 4 | 2 |
| Completed | 4 | 2 | 4 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
The primary efficacy endpoint will be based on the pre-treatment and post-treatment change in the number (%) of dystrophin positive fibers as measured in the muscle biopsy tissue on immunohistochemistry (IHC).
| percentage of dystrophin Pos. fibers | AVI-4658 (Eteplirsen) 30 mg/kg | Placebo - Week 24 Biopsy | AVI-4658 (Eteplirsen) 50 mg/kg | Placebo - Week 12 Biopsy |
|---|---|---|---|---|
| Change in the Number (%) of Dystrophin Positive Fibers | 23 (15.9 to 29.0) | -7.48 (-8.5 to -6.5) | 0.79 (-9.3 to 7.4) | -0.63 (-5.8 to 4.5) |
A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment Change from baseline: 6 Minute Walk Test (6MWT) - Intent to Treat population (ITT)
| Meters | 30 mg/kg Eteplirsen | 50 mg/kg Eteplirsen | Placebo |
|---|---|---|---|
| Change From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT) | -134.8 ± 72.36 | -2.3 ± 14.95 | -17.3 ± 14.03 |
A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment of the 6-MWT distance. Change from baseline: 6 Minute Walk Test (6MWT) - modified Intent-to-Treat population (mITT).
| Meters | 30mg/kg Eteplirsen | 50mg/kg Eteplirsen | Placebo |
|---|---|---|---|
| Change From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT) | -12.5 ± 1.50 | -2.3 ± 14.95 | -17.3 ± 14.03 |
Adverse events that occurred in \>30% of the overall patient population across treatment arms.
| Number of patients | AVI-4658 (Eteplirsen) - 30mg/kg | AVI-4658 (Eteplirsen) - 50mg/kg | Placebo |
|---|---|---|---|
| Procedural Pain | 1 | 3 | 3 |
| Oropharyngeal Pain | 3 | 0 | 3 |
| Hypokalemia (a known side effect of steroids) | 2 | 2 | 2 |
| Cough | 1 | 1 | 2 |
| Extremity Pain | 0 | 1 | 3 |
Frequency of AEs that the study physician considered to be any of the following: Related; Possibly related; or Probably related to eteplirsen.
| Number of patients | AVI-4658 (Eteplirsen) - 30mg/kg | AVI-4658 (Eteplirsen) - 50mg/kg | Placebo |
|---|---|---|---|
| Intermittent Nausea (mild) | 0 | 0 | 1 |
| Other AEs related to eteplirsen | 0 | 0 | 0 |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AVI-4658 (Eteplirsen) - 30mg/kg | — | 0/4 (0%) | 4/4 (100%) |
| AVI-4658 (Eteplirsen) - 50mg/kg | — | 0/4 (0%) | 4/4 (100%) |
| Placebo | — | 0/4 (0%) | 4/4 (100%) |
| Event | AVI-4658 (Eteplirsen) - 30mg/kg | AVI-4658 (Eteplirsen) - 50mg/kg | Placebo |
|---|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 1/4 | 3/4 | 3/4 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/4 | 0/4 | 3/4 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/4 | 1/4 | 3/4 |
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 0/4 | 2/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/4 | 1/4 | 2/4 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 1/4 | 0/4 | 2/4 |
| Balance DisorderNervous system disorders | 1/4 | 2/4 | 0/4 |
| HeadacheNervous system disorders | 1/4 | 0/4 | 2/4 |
| PyrexiaGeneral disorders | 1/4 | 0/4 | 2/4 |
| HypokalaemiaMetabolism and nutrition disorders | 2/4 | 2/4 | 2/4 |
| Age, Categorical(Participants) | AVI-4658 (Eteplirsen) 30 mg/kg | AVI-4658 (Eteplirsen) 50 mg/kg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 4 | 4 | 4 | 12 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | AVI-4658 (Eteplirsen) 30 mg/kg | AVI-4658 (Eteplirsen) 50 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 9.3 ± 0.50 | 8.5 ± 1.29 | 8.5 ± 1.73 | 8.8 ± 1.22 |
| Sex: Female, Male(Participants) | AVI-4658 (Eteplirsen) 30 mg/kg | AVI-4658 (Eteplirsen) 50 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 4 | 4 | 4 | 12 |
| Region of Enrollment(participants) | AVI-4658 (Eteplirsen) 30 mg/kg | AVI-4658 (Eteplirsen) 50 mg/kg | Placebo | Total |
|---|---|---|---|---|
| United States | 4 | 4 | 4 | 12 |
The record gives a start of Jul 2011, a primary completion of Feb 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →